ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2462

Mitochondrial-Mediated Neutrophil Activation in Dermatomyositis (DM) and Inclusion Body Myositis (IBM): Insights into Pathogenesis and Therapeutic Implications

Jorge Armando Gonzalez-Chapa1, Jemima Albayda2, Begum Horuluoglu3, Despina Michailidou1, Marina Barguil Macedo1, Lisa Christopher-Stine2, Ingrid Lundberg4 and Christian Lood1, 1University of Washington, Seattle, WA, 2Johns Hopkins University, Baltimore, MD, 3Karolinska Institutet, Stockholm, Sweden, 4Division of Rheumatology, Department of Medicine, Karolinska Institutet; Department of Gastroenterology, Dermatotology, Rhematology, Karolinska Universitetssjukhuset, Stockholm, Sweden

Meeting: ACR Convergence 2023

Keywords: Biomarkers, dermatomyositis, Mitochondrial Dysfunction, Myopathies, neutrophils

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, November 14, 2023

Title: Abstracts: Muscle Biology, Myositis & Myopathies – Basic & Clinical Science I

Session Type: Abstract Session

Session Time: 2:00PM-3:30PM

Background/Purpose: Dermatomyositis (DM) and inclusion body myositis (IBM) are characterized by muscle weakness and inflammation, with emerging evidence of mitochondrial and neutrophil involvement. Prior work from our group has demonstrated the important role of mitochondrial-derived danger-associated molecular patterns to promote neutrophil activation in inflammatory conditions. In the current study, we aimed to investigate whether patients with myopathies had elevated levels of extracellular mitochondrial biomarkers promoting neutrophil-mediated inflammation.

Methods: Plasma samples were obtained from patients with inclusion body myositis (IBM, n=46), dermatomyositis (DM, n=40), and healthy individuals (HC, n=40) from Karolinska Institutet, Stockholm, Sweden; Johns Hopkins, Baltimore, USA; and University of Washington, Seattle, USA. DM patients were further categorized based on the presence of autoantibodies towards MDA5 (n= 19) and TIF1-gamma (n=21). Plasma levels of neutrophil-derived calprotectin and neutrophil elastase (NE)-DNA complexes, as well as mitochondrial-derived GDF-15, and N-formyl methionine (fMET), which are valuable indicators of potential mitochondrial driven-pathological processes, cellular stress, and/or tissue damage, were measured using ELISA. Statistical analysis was performed using GraphPad Prism 9.4.0.

Results: Calprotectin levels were significantly elevated in DM patients, with the highest concentrations observed in those with MDA5 subtype (Figure 1A). Patients with IBM had similar levels of calprotectin as compared to HC. In contrast, levels of neutrophil extracellular traps, NETs (NE-DNA), were elevated in both DM and IBM patients, as compared to HC (Figure 1B). Both IBM and DM patients exhibited higher levels of mitochondrial-derived fMET and GDF-15 as compared to HC (Figures 1C and D), supporting a role for mitochondrial dysfunction and extrusion in these myopathies. Levels of GDF-15 and fMET were strongly correlated in DM but surprisingly no association was found in IBM (Figures 2A and B). Of note, consistent with other inflammatory conditions, levels of mitochondrial-derived fMET correlated strongly with neutrophil activation marker calprotectin in both IBM and DM (Figures 2C and D) suggesting that similar mechanisms, e.g. activation of neutrophils through fMET receptor FPR1, may operate in these subgroups of myopathies.

Conclusion: Our findings reveal distinct biomarker profiles in DM and IBM, highlighting the potential roles of mitochondria and neutrophils in myopathies. The differences and similarities observed between the subgroups suggest that calprotectin and NETs may play distinct roles in DM and IBM, while elevated levels of mitochondrial-derived fMET and GDF-15 indicate the potential involvement of mitochondrial dysfunction suggesting a common pathological mechanism. Further studies are warranted to determine the role of mitochondria and neutrophils in disease pathogenesis, as well as their clinical implications in monitoring disease activity.

Supporting image 1

Figure 1. Neutrophil and mitochondrial biomarkers in IBM and DM.
Levels of A) Calprotectin, B) NE-DNA, C) fMET, and D) GDF_15 in patients with Inclusion Body Myositis (IBM), Dermatomyositis (DM), and Healthy Controls (HC). DM patients were subdivided into MDA5 (n=19) and TIF_1 gamma (n=21) subgroups. Mann-Whitney U test was used for statistical analyses.

Supporting image 2

Figure 2. DM and IBM correlations between neutrophil and mitochondrial biomarkers
Correlations between GDF_15 and fMET in A) DM and B) IBM patients. Correlations between calprotectin and fMET in C) DM and D) IBM patients.
Spearman’s correlation coefficient test.


Disclosures: J. Armando Gonzalez-Chapa: None; J. Albayda: Amgen, 5, Janssen, 5; B. Horuluoglu: None; D. Michailidou: Chemocentryx, 1; M. Barguil Macedo: None; L. Christopher-Stine: None; I. Lundberg: Argenx, 6, Astra-Zeneca, 5, Boehringer-Ingelheim, 6, Bristol-Myers Squibb(BMS), 1, Corbus Pharmaceutical, 6, EMD Serono Research & Development Institute, 6, Janssen, 6, Kezar, 6, Novartis, 11, Octapharma, 6, Orphazyme, 6, Pfizer, 1, Roche, 11, Xencor, 6; C. Lood: Amytryx, 5, Boehringer-Ingelheim, 5, Bristol-Myers Squibb(BMS), 5, Citryll, 2, Eli Lilly, 5, Gilead, 5, Horizon Therapeutics, 5, Pfizer, 5, Redd Pharma, 5, 11.

To cite this abstract in AMA style:

Armando Gonzalez-Chapa J, Albayda J, Horuluoglu B, Michailidou D, Barguil Macedo M, Christopher-Stine L, Lundberg I, Lood C. Mitochondrial-Mediated Neutrophil Activation in Dermatomyositis (DM) and Inclusion Body Myositis (IBM): Insights into Pathogenesis and Therapeutic Implications [abstract]. Arthritis Rheumatol. 2023; 75 (suppl 9). https://acrabstracts.org/abstract/mitochondrial-mediated-neutrophil-activation-in-dermatomyositis-dm-and-inclusion-body-myositis-ibm-insights-into-pathogenesis-and-therapeutic-implications/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2023

ACR Meeting Abstracts - https://acrabstracts.org/abstract/mitochondrial-mediated-neutrophil-activation-in-dermatomyositis-dm-and-inclusion-body-myositis-ibm-insights-into-pathogenesis-and-therapeutic-implications/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology